Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy

OBJECTIVE: The efficacy and safety of olaparib, an oral poly(ADP-ribose) polymerase (PARP) inhibitor, was investigated in a subgroup of patients with germline BRCA1/2 mutated (gBRCA1/2m) advanced ovarian cancer who had received ≥3 prior lines of chemotherapy. Primary data from this Phase II study (S...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Gynecol Oncol
Hauptverfasser: Domchek, Susan M, Aghajanian, Carol, Shapira-Frommer, Ronnie, Schmutzler, Rita K, Audeh, M William, Friedlander, Michael, Balmaña, Judith, Mitchell, Gillian, Fried, Georgeta, Stemmer, Salomon M, Hubert, Ayala, Rosengarten, Ora, Loman, Niklas, Robertson, Jane D, Mann, Helen, Kaufman, Bella
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2015
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4992984/
https://ncbi.nlm.nih.gov/pubmed/26723501
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2015.12.020
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge